Articles related to CME

This educational program aims to improve the knowledge and comprehension of the clinical trial and real-world evidence for the CDK4/6i class among HCPs. A greater percentage of patients with HR+/HER2 metastatic breast cancer (mBC) will have access to this therapeutic option by filling care gaps linked to CDK4/6i usage. The course will largely center on three (3) core learning areas: best practices in CDK4/6i therapy management, the significance of real-world evidence (RWE) in treatment decision-making, and CDK4/6i in mBC: indications, clinical data, and RWE.

This course is intended to provide information from an unbiased viewpoint on managing headaches while treating Chiari malformation with either medication or surgical therapy. This course will combine lectures, patient insights, and expert panels. It will be offered in person, digitally through Microsoft Teams, and on-demand for all paid attendees for one month following the conference. After completing this course, participants will be able to identify more precise headache care techniques and understand when surgery is necessary, use logic and reason when treating patients with Chiari malformation and headaches, and determine the prevalence of headaches and Chiari malformation in the general population.

This CME program discusses how Bruton’s tyrosine kinase inhibitors (BTKi) have improved treatment for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and other B-cell malignancies. However, due to adverse events and treatment resistance, many patients discontinue treatment. A new generation of BTKi with a different mechanism of action (MOA) is emerging as a possible alternative. The program presents four modules that discuss the MOAs of covalent and non-covalent BTKi, current practices for using BTKi in treatment of CLL and MCL, the efficacy and safety data for novel BTKi, and the potential role of non-covalent BTKi in future treatment plans.

Poor adherence to treatment is the biggest predictor in relapse in serious mental illnesses. In this 0.5-CME credit activity, the panel discusses key contributors to the adherence challenge and strategies for improving adherence – including use of newer, better tolerated therapies. Available in video, podcast, and text.

Following participation in this educational activity, hematologists/oncologists, nurses, pharmacists, and other members of the interprofessional team involved in the management of DLBCL patients should be better able to:

Because each patient reports unique challenges, there is no “one size fits all” approach to managing cancer-associated venous thrombosis (CAT). Thrombosis is a complication that HCPs are not recognizing early enough in the face of multiple options for appropriately treating and managing CAT; additionally, there is a lack of awareness of new CAT management clinical data. Although the morbidity and mortality of VTE in cancer patients remain high, unfortunately, its management is not given the same priority. And although recommendations suggest an individualized approach to managing these patients, clinical practice adoption is slow. Published guidelines and clinical trial data do not always correspond to real-world practice and prescribing practices. As a result, many existing CAT management protocols must be updated as new guidance is warranted.